肾癌组织中HMGB1、MMP9的表达与临床分期、预后的相关性研究

目的  探讨高迁移率族蛋白B1（HMGB1）、基质金属蛋白酶9（MMP9）在肾癌组织中的表达，及与肾癌临床病理特征、预后的相关性。方法  采用免疫组织化学、实时定量聚合酶链反应法，检测67例肾透明细胞癌患者癌组织、癌旁组织中HMGB1、MMP9的表达，采用Person法分析其与临床病理学特征的相关性，采用Kaplan-Meier方法进行生存曲线分析，采用Cox比例风险模型分析影响患者预后相关因素。结果  肾癌组织中HMGB1、MMP9表达高于癌旁肾组织，差异有统计学意义；肾癌肿瘤TNM分期、淋巴结转移度、肿瘤直径与HMGB1、MMP9表达相关，而不同性别、年龄间HMGB1、MMP9的表达差异无统计学意义；HMGB1、MMP9低表达肾癌患者的生存期要高于中、高表达患者，HMGB1、MMP9的表达水平与预后呈负相关；HMGB1、MMP9、肿瘤TNM分期、淋巴结转移度是影响肾癌患者预后的独立危险因素。结论  HMGB1、MMP9可能在肾癌的浸润、转移机制中起着非常重要的作用，联合检测肾癌组织中HMGB1和MMP9的表达水平可能有助于评估肾癌的生物学特征和患者预后。

Expressions of HMGB1 and MMP9 and their clinical significance in renal carcinoma

Objective To investigate the expressions of high mobility group box 1 protein (HMGB1) and matrix metalloproteinase 9 (MMP9) in renal carcinoma tissue and their relationship with clinic pathological characteristics of renal carcinoma. Methods The expressions of HMGB1 and MMP9 in 67 patients with renal carcinoma were determined using real-time PCR and immunohistochemistry. Statistical analysis was then conducted using Person, Kaplan-Meier and Cox proportional hazards analyses. Results The expressions of HMGB1 and MMP9 in the carcinoma tissues were higher than those in the para-carcinoma tissues, and closely related to TNM stage, lymph node ratio and diameter of tumor. The life time of the patients with low expressions of HMGB1 and MMP9 was longer than the patients with high expressions. The expressions of HMGB1 and MMP9 were negatively correlated with the prognosis. HMGB1, MMP9, TNM stage and lymph node metastasis were independent risk factors for the prognosis of renal carcinoma. Conclusions HMGB1 and MMP9 may play crucial roles in the infiltration and metastasis of renal carcinoma. Joint detection of HMGB1 and MMP9 in renal carcinoma tissues may help to evaluate the prognosis of patients.